- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Snapshot for MannKind Corp (MNKD)
| Open: | 5.4000 | Day's Range: | 5.2800 - 5.4000 | Volume: | 6,247,624 |
|---|---|---|---|---|---|
| Previous Close: | 5.3100 | 52wk Range: | 1.5800 - 5.4450 | 1-Yr Rtn: | +214.41% |
Key Statistics for MNKD
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.8300 |
| Est. EPS (USD) (12/2013) | -0.4370 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 1,553.31 |
| Shares Outstanding (M) | 290.88 |
| 30 Day Average Volume | 5,590,976 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 29,097.2626 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for MNKD
Company Profile & Key Executives for MNKD
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Companys lead investigational product candidate is the Technosphere Insulin System.
| Alfred E MannChairman/CEO | Hakan S EdstromPresident/COO |
| Matthew J Pfeffer "Matt"VP/CFO | David B ThomsonVP/Secy/General Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
MNKD News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page